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Abstract:  
Microglia has been found to diversify its function by cancerous cells or in a cancerous 
environment, thereby contributing to cancer growth and metastasis. Its 
immuno-activity, however, can be modulated by interleukin-12. So a strategy was 
designed using AAV2 carrying IL-12 to activate microglia then to eliminate cancerous 
cells. The transduction efficacy of AAV was evaluated with AAV2 encoding GFP and 
IL-12 on cancerous and CNS cells. The bioactivity of microglia modulated by IL-12 
was examined and death receptors 4 and 5 were detected on cancerous cells. The 
effects of IL-12 and AAV2/IL-12 on microglial cytoxoxicity were evaluated too. The 
results demonstrated human cell line DBTRG, surgical specimen of GBM, and rat 
astrocyte expressed GFP quite well. Tremendous IL-12 secretion was detected in 
DBTRG, RG2, and astrocyte after transfection of AAV2/IL-12. TRAIL releasing and 
phagocytotic activity of microglia were significant, increasing (p<0.05) after the 
stimulation of IL-12. DR4 and DR5 were expressed in all of the examined GBM cells. 
MTT assay of microglial cytotoxicity elicited significant increase (p<0.05) when the 
IL-12 protein or RG2-secreting IL-12 could have contact with microglial cells. 
Conclusively, AAV2 is an effective vector in transferring therapeutic genes such as 
IL-12 to induce or enhance microglial anti-cancer activity.  
 
Keywords: adeno-associated virus; glioblastoma multiforme; microglia; 
interleukin-12; TRAIL; phagocytosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction:  
Interleukin-12 
Among the results of recent anti-cancer research, immuno-modulation with 
cytokines is one of the modalities with the most potential.1-4 Many pro-inflammatory 
cytokines have been investigated and clarified for their anti-cancer effects and 
mechanisms. Among these, interleukin-12 (IL-12) exhibits the most power in 
enhancing either innate or adaptive responses for anti-cancer activity. In the cascade 
of IL-12 activity, the antigen presenting cells, such as dendritic cells, macrophage, and 
neutrophile, produce and secrete IL-12 after encountering the invading pathogen or 
transformed cells. Subsequently, IL-12 induces proliferation of hematopoietic 
progenitor cells and generation of IL-3 and stem-cell factors, along with stimulating a 
pre-activated natural killer cell, natural killer T cell, and cytotoxic T cell to increase in 
number and cytotoxicity and to secrete interferon- γ , granulocyte-macrophage 
colony-stimulating factor, tumor necrosis factor and IL-8. In addition, IL-12 may 
facilitate the TH1 pathway to promote the naïve T cells to effectiveness and becoming 
memory TH1 cells.5 In anti-cancer activity, IL-12 has been demonstrated to stimulate 
NK cells or T cells to enhance anti-angiogenesis through secreting interferon-γ, to 
induce tumor cytotoxicity by secreting the family of tumor necrosis factor (TNF), and 
to promote tumor antigen-specific adaptive immunity through the TH1 pathway.6 
Nevertheless, the adverse effect of systemic administration of pro-inflammatory 
cytokines shown in the human clinical trail of interleukin-12 protein was found to be 
extremely harmful.7 Furthermore, from the experience of clinical practice, malignant 
brain tumors always recur or relapse within a short period after the complete initial 
treatment, even in the imaging curative cases.8-10 Therefore, a superior method should 
be designed as a long term expression of cytokines and local tissue affection for the 
purpose of maximal therapeutic effectiveness and restricted systemic toxicity.   
Adeno-associated virus  
For the purpose of long term expression and local delivery of cytokine, an 
effective vehicle to transfer the cytokine into the focal tissue is superior to direct 
protein injection or naked DNA implantation. In the choice of a mediating vector, 
acuminating evidence has illuminated the feasibility of adeno-associated virus (AAV) 
in genomic transportation.11,12 AAV is of the parvovirus family and is characterized by 
being deficient in replication, non-pathogenic to humans, and able to transfect most 
cell types.13 The genes mediated by AAV could be expressed up to 15 months and 
sustained in high levels during the 2nd to 4th months when inoculated in the mouse 
brain.14 Its competence and safety have been elucidated in several clinical human 
trials from early 1996, where cystic fibrosis was converted with AAV2 transferring 
the cystic fibrosis transmembrane conductance gene into lung tissue, to 2007, where 
advanced Parkinson’s disease was treated with AAV2 transferring the glutamic acid 
decarboxylase gene into the subthalamic nucleus.15,16  
Microglia 
Microglia - the central nervous system (CNS) immune cells - comprise 2-20% of 
the population of CNS cells, which execute the defense function against invading 
microbes and execute the clearance of transformed cells.17,18 Prospectively, in a tumor 
environment, microglial cells infiltrate the tumor considerably more than other 
peripheral immune cells, which have been estimated to be up to 10-34% of the 
composition of tumor mass.19 Microglial cells represent an antigen presenting 
function in CNS through major histocompatibility complex type 2 and present 
phagocytotic ability. Furthermore, they generate cytokines, including IL-1α, IL-β, 
IL-6, IL-12, IL-16, IL-23, TNF-α, and transforming growth factor and chemokines, 
including MCP-1, MIP-1, IL-8, MIG, and IP-10.20,21 Nevertheless, the immune 
performance of microglia in the tumor environment was diversely and continuously 
affected by the tumor-released factors, such as immunosuppressive cytokines, that 
potentiated to loss or reduction in their antigen presenting activity and innate immune 
response.22,23 Furthermore, the extracellular matrix protease released by microglia 
which infiltrated the tumor and was changed in behavior by the tumor-released factor 
was postulated to promote the invasion and migration of tumor cells.24 Therefore, 
readjusting or reinforcing the native immune activity of tumor-infiltrating microglial 
cells will achieve better anti-cancer activity than the peripheral immune cells by 
disrupting the phenomenon of tumor-promoted effects of microglial cells and 
restoring the anti-tumor ability of the abundant tumor-infiltrating microglial cells. In 
this study, we constructed AAV type 2 (AAV2) encoding IL-12 to survey the 
expressive efficacy of astrocyte, microglial cell and glioblastoma multiforme (GBM) 
cell and to judge the feasibility of AAV2 in malignant brain tumor therapy. Further, 
owing to the high composition of microglia in tumor mass, we evaluated the 
anti-tumor effect of microglia pre- and post-stimulation with IL-12 on account on its 
secretion of interferon-gamma (IFN-γ), nitric oxide, tumor necrosis factor-alpha 
(TNF-α ), and TNF related apoptosis inducing ligands (TRAIL) and also its 
phagocytotic activity.  
 
 
 
 
 
Materials and methods:  
Construction of AAV2 encoding IL-12 
The full length cDNA of IL-12 (InvivoGen) was amplified using polymerase 
chain reaction and subcloned into pAAV-MCS (Stratagene), then verified by DNA 
sequencing (Protec). The production of AAV2 encoding IL-12 included 5 main steps - 
transformation of E-coli, plasmid extraction, culture of HEK 293 cells, package of 
AAV2 in 293 cells and AAV2 purification. In brief, E-coli (ECOS 101) cells were 
used as competent cells and transformed by pAAV-RC (Stratagene), pHelper 
(Stratagene), or pAAV-GFP, which were cultured with 2YT –Broth A50 (Invitrogen) 
medium containing ampicillin (50μg/ml) at 37℃. The transformed E-coli were 
resuspended in 2YT-Broth medium A50 and prepared for extraction of the three 
plasmids. The plasmid DNAs were purified with a plasmid Mega preparation kit 
(Qiagen). Each of the extracted plasmids was quantified with OD260/280. The frozen 
HEK 293 cells were thawed under 37℃ and cultured with DMEM (Cellgro), 10% 
FBS (Hyclone), and 1% penicillin/streptomycin (Gibco). The extracted plasmids, 
pAAV-RC, pAAV-IL-12, and double the pHelper, were mixed and shaken with CaCl2. 
The mixture was spread into HEK 293 cell culture dish and incubated with DMEM, 
10% FBS, and 1% P/S at 37℃ for AAV-GFP package. The packaged AAVs were 
purified through heparin column (Heparin Actigel Sterogen).  
Transduction of rAAV2 on targeted cells 
Five cell types – Human GBM cell line DBTRG, rat GBM cell line RG2, primary 
culture of rat microglia and rat astrocyte, and primary culture of human GMB cells – 
were surveyed for rAAV2 transduction efficacy. The RG2 and BV2 were purchased 
from FIRDI Taiwan, astrocytes were extracted from the embryonic brain of rat, and 
human GBM cells were cultured from a surgical specimen proven by a pathologist. 
1x105 cells of DBTRG were spread into each well of 6-well plate and cultured with 
10% FBS, DMEM (Gibco 11995), and Penicillin-Streptomycin sulfate (Gibco 
15140-122) for 24 hours. 100μl AAV2-GFP (4.28x1010 particle/ml) was added in and 
inspected daily under florescent microscope to the fourth day. The expression of GFP 
was evaluated and pictured at 24 hours and at four days after the addition of rAAV2. 
The same procedure was practiced on the other cell types.  
ELISA assay of IL-12 expression 
Five cell types –– rat GBM cell line RG2, primary culture rat astrocyte, 
microglia cell line BV2, human GBM cell line DBTRG and HEK 293 –– were 
transfected by AAV2/IL-12 and were evaluated for IL-12 expression. 1x105 cells of 
each cell type were transferred to 6 wells of a 96-well plate and cultured with 10% 
FBS, DMEM, and Penicillin-Streptomycin sulfate for 24 hours. AAV2-mIL-12 in 
three concentrations –– 1x1010, 1x1011, and 1x1012 particle/ml –– were added into 
cultured cells with one concentration to two wells and were incubated for 4 days. The 
supernatant of each well was aspirated and span, then the upper clear fluid was 
obtained for estimating the mIL-12 concentration by ELISA Kit (M1270 Quantikine). 
The same procedures were performed with AAV2-GFP instead of AAV2-mIL-12 for 
negative control. 
ELISA assay of microglia-secreted cytokines 
Mouse IL-12 protein (mIL-12) was purchased from eBioscience and stored at 4
℃. 5x104 BV2 cells were transferred to each well of a 96-well microplate then 
cultured with 2% FBS for 24 hours. The experiment was divided into three groups – 
non-stimulated, IL-12-stimulated, and LPS-stimulated. Therefore, 100ng mIL-12 and 
LPS were added into 18 wells individually to active the BV2 cells. After 24, 48, and 
72 hours of stimulation, the supernatant was aspirated and collected for detection of 
IFN-γ. The same procedures were repeated for detection of TNF-αand TNF-related 
apoptosis inducing ligand (TRAIL). The amount of IFN- γ  and TNF-α  were 
estimated with ELISA kit (Quantikine, R&D) following the product introduction. The 
TRAIL was detected with rat anti-mouse TRAIL/TNFSF10 monoclonal antibody as 
the primary antibody and biotinylated anti-rat IgG antibody as the secondary antibody 
(R&D systems, Inc.).  
Western blot assay of TRAIL receptor 
A total of 6 human cancer cell types –– GBM cell lines DBTRG, G5T-VGH, 
GBM 8401, GBM 8901, along with pathologically verified GBM specimen No. 3 and 
No. 4 –– were evaluated by SDS-PAGE for death receptors 4 (DR4) and 5 (DR5). 
The protein was extracted with lysis buffer PRO-PREP (Asia life Science). Before 
that, the tissue was ground with ceramic zirconium oxide beads. The protein 
concentration was determined by BCA assay read by ELISA reader at OD 590 nm. 
The protein was analyzed on 10% polyacrylamide gel by SDS-polyacrylamide gel 
electrophoresis and transferred electrophoretically to nitrocellulose membranes at 400 
mA for 2.5 hr. Goat anti-human TRAIL R1 and R2 antibodies were used as primary 
antibody. Rat anti-goat IgG couple with horseradish peroxidase was used as 
secondary antibody and the activity of peroxide was detected with enhanced 
chemiluminescence.  
Phagocytosis of microglia 
BV2 cells were cultured in a 10cm culture dish with 10% FBS + DMEM. The 
phagocytotic analysis was done using a 96-well microplate with cover and 
fluorescence microplate reader (Vybrant, Phagocytosis Assay Kit). Briefly, 4x105 BV2 
cells were transferred into a well for a total of 18 wells and incubated with 10% 
FBS+DMEM. Six wells without BV2 cells were added in 150 µL of DMEM as 
negative control. 18 wells were equally divided into IL-12-treated, LPS-treated and 
non-treated three groups. The stimulating reagent 100ng IL-12 or 100ng LPS was 
added and the culture medium was changed to 2% FBS + DMEM. After 18 hrs of 
incubation, 100 µL of prepared E-coli fluorescent BioParticle suspension (Vybrant) 
was added into each well then incubated 2 hrs. 100 µL trypan blue was added in and 
incubated for one minute after removing the BioParticle loading suspension by 
vacuum aspiration. The fluorescence was read at ~480 nm excitation and ~520 nm 
emission. The phagocytotic efficacy was estimated with the formula of “% Effect = 
Net Experimental Reading/Net Positive Reading x 100%”.  
MTT assay of microglial cytotoxicity on RG2 cells 
MTT solution (5mg/ml) was diluted with PBS in a ratio of 1:9 and stored at 2-6
℃ for further utility. Two different culture modes were performed:  the co-culture 
mode using a 96-well plate and the trans-well culture mode using a trans-well 96-well 
plate. Four conditions were set in the co-culture mode, which included 2ml MTT 
medium only, 2ml MTT medium + 5x104 RG2 cells, 2ml MTT medium + 5x104 RG2 
cells + 5x104 BV2 cells, and 2ml MTT medium + 5x104 RG2 + 5x104 BV2 cells + 
100ng IL-12. The same conditions were applied in the trans-well mode, however, 
RG2 cells were incubated on the bottom plate with 2 ml MTT medium and BV2 cells 
were incubated on the upper plate with 2ml MTT medium. The plates were incubated 
in a 37℃ incubator for 4 hours. After centrifugation of the plate at 2000 rpm for 5 
minutes, the upper fluid of every well was removed and 1 ml DMSO was added. The 
plate was incubated for 5 minutes then transferred to the reader for measurement of 
absorbance at 590 nm.  
MTT assay of microglia on AAV2/IL-12-transfected RG2 cells 
The procedures were the same as above method except the experimental groups 
were changed to 5x104 RG2 cells, 5x104 AAV2/IL-12-transfected RG2 cells, 5x104 
RG2 + 5x104 BV2 cells, 5x104 AAV2/IL-12-transfected RG2 cells + 5x104 BV2 cells 
in co-culture model and 5x104 RG2 cells, 5x104 AAV2/IL-12-transfected RG2 cells 
on the bottom plate and 5x104 BV2 cells on the upper plate in the trans-well model. 
Statistical Analysis 
The data is depicted with mean value ± standard deviation. Student’s t-test was 
applied to examine the difference when only two groups were compared. For 
comparison of multiple groups, one-way ANOVA with Bonferroni post test was 
applied. The difference was assumed to be significant when p<0.05.  
 
 
 
 
 
Results: 
GFP expression of targeted cells 
All of the 5 targeted cells types could be transfected by AAV2/GFP and 
expressed GFP after 4 days incubation. In cancer cells, the expression of GFP of 
human cell line DBTRG and GBM cells from excised specimen were near 100%, 
however, the RG2 cells displayed a lower expression rate of near 20% (Fig. 1). In 
CNS cells, the rat astrocytes illustrated good expression of GFP as well as the DBTRG, 
but the rat microglial cells showed moderate expression between the DBTRG and 
RG2 (Fig. 1). 
Secretion of IL-12 of targeted cells 
The DBTRG cells exhibited the highest ability, even greater than HEK 293 in the 
secretion of IL-12 after transfection of AAV2/IL-12. The astrocytes and RG2 cells 
could express IL-12 in abundant amounts, too. Nevertheless, microglial cell line BV2 
didn’t express detectable IL-12 after four days of transduction. All of the five cell 
types that transfected with AAV/GFP did not secrete IL-12 (Tab. 1).  
Cytokines secreted from BV2 after IL-12 stimulation 
The BV2 didn’t secrete detectable IFN-γ in either the non-stimulated (control 
group), the IL-12-stimulated, or the LPS-stimulated group. In contrast, the BV2 
secreted substantial TNF-α, over the estimating scale, after stimulating by LPS. BV2, 
however, secreted only minimal TNF-α(27.3±9.2pg/ml) after the stimulation of IL-12. 
The t-test disclosed no significant difference increasing of TNF-αin IL-12-stimulated 
group compared with the non-stimulated group, which had a level of 9.7±6.1 pg/ml 
(Fig. 2). The BV2 stimulated by IL-12 also secreted TRAIL, which was 827.2±162.6 
pg/ml after 6 hrs stimulation, 755.2±46.4 pg/ml after 12 hrs stimulation , and 828.8±
111.3 after 24 hrs stimulation. Interestingly, the LPS didn’t stimulate BV2 to secrete 
TRAIL as well as IL-12 as the levels were 640.0±20.3 pg/ml, 632.8±10.1 pg/ml, and 
640.0±20.2 pg/ml after 6, 12, and 24 hrs stimulation. The ANOVA analysis elicited 
significant differences between the three groups, and the IL-12-stimulated group 
exhibited significant differences with the LPS-stimulated and non-stimulated groups 
in all three time points (Fig. 3). 
Expression of death receptor of tumor cells 
All of the 6 tested GBM cell types – DBTRG, G5T-VGH, GBM 8401, GBM 
8901, GBM specimen No. 3, and GBM specimen No. 4 – expressed DR4 and DR5 by 
western blot assay (Fig. 4). 
Phagocytotic activity of BV2 
The Phagocytotic activity of BV2 was enhanced obviously by either IL-12 or 
LPS. The phagocytotic efficacy was 76.7±12.9% in IL-12-stimulated BV2 and 100.0±
7.6% in LPS-stimulated BV2. The ANOVA analysis elicited significant differences 
between the three groups. The phagocytotic activity in BV2 of the IL-12-stimulated 
group exhibited significant differences with the non-stimulated groups (Fig. 5).  
Cytotoxicity of BV2 and IL-12-enhanced BV2 on RG2 cells  
The cytotoxicity of BV2 on the GBM cells RG2 was evaluated by MTT assay. 
The IL-12-stimulated BV2 cells exhibited significantly increasing cytotoxicity on 
RG2 cells either in co-culture or trans-well model. In contrast, the 
non-IL-12-stimulated BV2 cells exhibited no significantly increasing cytotoxicity on 
RG2 cells in both models (Fig. 6). In the secondary MTT assay of BV2 cytotoxicity, 
only the group of BV2 cells co-cultured with AAV2/IL-12-transfected RG2 cells 
displayed significantly increasing cytotoxicity. Differing from the experiment of 
IL-12 protein stimulation, the trans-well model of BV2 plus AAV2/IL-12 showed no 
cytotoxic activity of the BV2 cells. This phenomenon was interpreted as showing that 
BV2 cells could not be stimulated by the RG2-secreted IL-12 since BV2 cells were 
incubated on the upper plate. Furthermore, the survival of RG2 cells exhibited no 
difference after being transfected by AAV2/IL-12 as compared with the 
non-transfected cells (Fig. 7). 
 
 
 
Discussion: 
AAV2 application on the therapy of malignant brain tumor 
AAV has been verified as a competent vehicle to transfer therapeutic genes into 
many cell types of animals and humans,11,25 but its transductive efficiency still 
exhibits cell type-dependency. From the results of this experiment, the human GBM 
cells displayed remarkable AAV transduction to express GFP and IL-12, but the rat 
GBM cells disclosed weak transduction by AAV. In CNS cells, in contrast to rat 
astrocyte and rat microglia, which showed good transduction by AAV2, the cell line 
BV2 displayed very weak expression of IL-12 after being transfected by AAV2/IL-12. 
Therefore, it is important to inspect the transductive efficiency of AAV-targeted cells – 
cancer cells or tumor-infiltrated cells – if AAV is to be considered as a vector carrying 
therapeutic genes. The hypothesis for treatment of malignant brain tumor by local 
AAV2 delivery presumes to follow the sequential events from AAV2/IL-12 
transfecting to cancer cells, to cancer cells expressing IL-12 to induce or enhance the 
cytotoxicity of tumor-infiltrated microglial cells and, further, to eliminate cancer cells. 
Under this strategy, the undesired side effects from excessive IL-12 will be reduced 
when IL-12-secreting cancer cells are destroyed by microglial cells – since the 
microglial cells don’t secrete IL-12.  
Strategy of AAV2/IL-12 mediated immunotherapy 
Malignant brain tumor is still an incurable and fatal cancer despite the current 
therapeutic modalities and it usually relapses or recurs within 1-2 years.8,10 The 
majority of this failure is highly related to the immune escape of cancer or the 
immune reduction of the host.26,27 Therefore, fundamentally, to restore or to augment 
the innate or adaptive immune activity could overcome this situation of decline. 
Microglia, the resident immune cell, naturally represents antigen-presenting and 
innate immunity in CNS and has been found infiltrating malignant brain tumors. In 
acuminating evidence, however, their functions were converted from cancer-defense 
to cancer-contribution by cancerous cells or cancerous microenvironment.24,28 
Therefore, a therapeutic strategy for brain cancer can be to enhance or reform the 
anti-cancer tumor ability of microglia. In this study, a microglial cell was confirmed 
to secrete TRAIL and increased phagocytosis after stimulation of IL-12. In contrast 
with this, microglia did not express significant, IFN-γ(data not shown) and TNF-α
after stimulation of IL-12.  
Anti-cancer mechanism of microglia modulated by IL-12 
TRAIL is a member of the TNF superfamily, referring to type II trans-membrane 
proteins, which triggers cell apoptosis through an extrinsic pathway.29 Different from 
TNF-alpha, TRAIL is characterized by specific identity of cancerous cells by binding 
TRAIL death receptors of cancerous cells to initiate apoptosis and by binding decoy 
receptors of normal cells to avoid death destiny.30 Several immune cells, such as 
dendritic cells, monocyte, macrophage, NK cells, and cytotoxic T cells were 
demonstrated to secrete TRAIL in many organs after stimulation with IFN-γ and 
LPS.31,32 Besides, microglia also showed its ability in secreting TRAIL after LPS 
stimulation.33 In this study, we examined the influence of IL-12 on microglia secreting 
TRAIL using LPS as positive control. The results derived from three repeats, however, 
illustrated that TRAIL secreted from microglia could be promoted by IL-12 but not by 
LPS.  
The TRAIL-induced apoptosis is highly depended on the TRAIL receptor on 
cancerous cells, so we interpreted the DR4 and DR5 in four human GBM cell lines 
and two excised GBM specimens. As expected, all the GBM cells expressed DR4 and 
DR5, which enhances the conviction of the feasibility of anti-cancer therapy by IL-12 
stimulating microglia through the TRAIL pathway. Other than this, phagocytosis, one 
of the powerful defensive bioactivities of microglia, also was strongly induced by 
IL-12. 
 
 
 
 
Conclusion: 
AAV2 is an effective vehicle to transfer therapeutic genes in anti-GBM therapy. 
Among the defensive bioactivities of microglia, phagocytosis and the TRAIL death 
pathway were documented to be induced by AAV2-mediated IL-12. The cytotoxocity 
of microglia on GBM cells were confirmed to be significantly increasing via the 
stimulation of AAV2-mediated IL-12 through the TRAIL death pathway and 
phagocytosis. In summary, microglial cells can be modulated by AAV2-mediated 
IL-12 to increase anti-cancer activity and play an important role in the therapy of 
malignant brain tumors. 
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Legends: 
Fig. 1A. Photographs of GBM cell lines, surgical specimens of GBM, and CNS cells 
caught under microscope 4 days after being co-cultured with AAV2-GFP. The left 
photograph was pictured under a green fluorescent microscope and the right under 
phase contrast. A: DBTRG cells were inspected under a green fluorescent microscope, 
left; under phase contrast, right (high power field, x400). B: RG2 cells (low power 
field, x100) and C: Surgical specimen No.1 (high power field, x400). D: Microglial 
(low power field x100). E: Astrocytes (high power field x400).  
Table 1: The secreting amount of IL-12 from BV2, astrocyte, HEK 293, RG2 and 
DBTRG were estimated 4 days after being co-cultured with AAV2/IL-12 in three 
different concentrations - 1x1010, 1x1011 and 1x1012 particle/ml. The data were the 
mean of three wells in the same concentrations. * IL-12 secretion from DBTRG was 
over the maximal datum (2000 pg/ml) of estimating scale in all three AAV2 
concentrations.  
Fig. 2: TNF-alpha secreted from BV2 after 24 hours stimulation of IL-12 protein. The 
ctrl. represented non-IL-12-stimulating group.  
Fig. 3: TRAIL secreted from BV2 after stimulation of IL-12 and LPS at the time 
intervals of 6 hrs, 12 hrs, and 24 hrs. The ctrl represented non-stimulating group. * 
p<0.05, significant difference of IL-12-stimulated group compared with LPS and ctrl 
at different time interval by ANOVA analysis.  
Fig. 4: The SDS-PAGE of DR4 and DR5 which were extracted from human GBM cell 
lines DBTRG, G5T-VGH, GBM8401, GBM9801, along with primary culture GBM 
cells No. 3 and No. 4.  
Fig. 5: The Phagocytotic activity of BV2 after stimulation of IL-12 and LPS. The 
phagocytotic efficiency was estimated with fluorescent particles engulfed by BV2 
cells. The ctrl represented the non-stimulated group. * P<0.05 versus control. 
Fig. 6: The cytotoxic effects of BV2 on RG2 with and without stimulation of IL-12 
protein were evaluated by MTT assay in trans-well and co-culture two different 
environments. The data of absorbance were collected and presented to 5 groups. * 
P<0.05, RG2+BV2+IL-12 in trans-well compared with RG2, RG2+BV2 in trans-well, 
or RG2+BV2 in co-culture; RG2+BV2+IL-12 in co-culture compared with RG2, 
RG2+BV2 in trans-well, and RG2+BV2 in co-culture.  
Fig. 7: The cytotoxic effect of BV2 on RG2 and AAV2-IL-12-transfected RG2 was 
evaluated by MTT assay in two different environments – trans-well and co-culture. 
The data of absorbance were collected and presented to 6 groups. RG2-AAV denoted 
RG2 cells transfected with AAV2/IL-12. * p<0.05, RG2-AAV+BV2 compared with 
the other groups. 
 








